Previous DRV dose and baseline genotypic susceptibility score did not negatively affect the efficacy of switching from DRV-containing ART to EVG/COBI/TAF/FTC plus DRV.
Switch to RPV/FTC/TAF from NNRTI/FTC/TDF-containing regimen associated with significant improvements in markers of renal and bone safety.
Efficacy and safety outcomes were independent of third agent and at Week 48 were consistent in patients 50 years of age or older.
Discontinuation for neuropsychiatric events more common for dolutegravir and comprised primarily sleep disturbances and insomnia; women, older adults, and patients initiating concurrent abacavir at increased risk.
After 48 weeks, switch to DRV/RTV plus 3TC from DRV/RTV plus TDF/FTC or ABC/3TC was well tolerated and associated with maintenance of virologic suppression without emergent resistance.
Four of 85 patients completing 24 weeks of dolutegravir treatment experienced virologic failure.
Similar virologic efficacy observed across disease and demographic subgroups.
Both regimens demonstrated high genetic barriers to resistance.
Low rates of psychiatric adverse events in DTG/ABC/3TC and ATV/RTV plus TDF/FTC treatment arms.
Insomnia was the most common dolutegravir-related psychiatric adverse event in all 4 examined trials.